TAGRISSO (AstraZeneca Pharmaceuticals LP)
Welcome to the PulseAid listing for the TAGRISSO drug offered from AstraZeneca Pharmaceuticals LP. This Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 1A2 Inducers [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | AstraZeneca Pharmaceuticals LP |
| NON-PROPRIETARY NAME: | osimertinib |
| SUBSTANCE NAME: | OSIMERTINIB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Kinase Inhibitor [EPC],Kinase Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 1A2 Inducers [MoA],Breast Cancer Resistance Protein Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2015-11-13 |
| END MARKETING DATE: | 0000-00-00 |
TAGRISSO HUMAN PRESCRIPTION DRUG Details:
| Item Description | TAGRISSO from AstraZeneca Pharmaceuticals LP |
| LABELER NAME: | AstraZeneca Pharmaceuticals LP |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 40(1-Jan) |
| START MARKETING DATE: | 2015-11-13 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0310-1349_d996494b-c0bc-42f2-9ecd-0b5216edc6f0 |
| PRODUCT NDC: | 0310-1349 |
| APPLICATION NUMBER: | NDA208065 |
Other OSIMERTINIB Pharmaceutical Manufacturers / Labelers:
